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Summary 
 
Background: Primary immunodeficiency disorders (PID) disrupt the proper functioning of the immune 
system. The prototypic PID is X-linked Agammaglobulinemia (XLA). This disorder is caused by mutations 
in the Bruton tyrosine kinase (Btk) gene and results in an arrest in B cell development which leads to a 
profound reduction of all classes of serum immunoglobulins (i.e antibodies). Patients with a lack of 
antibodies experience recurring bacterial infections during early childhood that can be fatal if not treated. 
Intravenous gammaglobulin replacement therapy (IVIg) is the standard treatment for XLA. It provides 
passive immunity thereby reducing the number and severity of infections as well as limiting many of the 
infectious complications. Early detection and treatment of XLA allows affected individuals to live a 
relatively normal life. 
Objective: The purpose of this study was to determine the molecular basis of XLA in South Africa using a 
direct sequence-based method to detect abnormalities in the Btk gene to aid clinical diagnosis of the 
disease. 
Methods : Male patients with a clinical diagnosis of XLA were included in this study. Genetic analysis 
was used to explore the exonic region of the Btk gene of 5 unrelated male patients and compared to 10 
healthy controls. Family members were followed up to determine carrier status, where possible. 
Results: Mutational analysis revealed Btk abnormalities in 4 of the 5 patients leading to a definitive 
diagnosis of XLA. Two of the three mutations found in this study have been previously described while 
one mutation appears to be novel. The novel mutation is a one base pair deletion in exon 16 which leads to 
the truncation of the Btk protein. Despite the clinical findings suggestive of XLA, no mutation was 
identified in the exonic region of the Btk gene of the remaining patient, indicating that this patient might 
have a different form of PID. Maternal follow-up confirmed the maternal inheritance pattern as all mothers 
screened were carriers of the Btk mutation present in the affected individual.  
Discussion : 
 Using a direct sequence-based method abnormalities were identified in the Btk gene of three patients.  
Molecular diagnosis coupled to clinical history of the patient provides a definitive XLA diagnosis. This 
study supports the use of molecular techniques in the diagnosis of PID and underlines the synergy that 
could be possible in a clinical setting. 
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Opsomming 
 
 
Agtergrond:  Primêre immuungebrek siektes (PIGS) word gekenmerk aan ‘n gebrek aan teenliggame in 
die immuunsisteem wat lei tot herhaalde infeksies in jong kinders wat fataal kan wees indien dit nie 
vroegtydig behandel word nie. Die prototype van die bekende PIGS is X-gekoppelde Agammaglobulinemia 
(XGA). Die siekte word veroorsaak deur mutasies in die Bruton Tirosien kinase (Btk) geen en lei tot ŉ 
stilstand in B sel ontwikkeling en gevolglik ŉ vermindering van alle klasse van serum immuunoglobulins 
(teenliggaam). Intraveneuse gammaglobulien vervangingsterapie(IVIg) is die standaard behandeling vir 
XGA.  Dit voorsien passiewe immunitiet en gevolglik verminder dit die getal en erns van infeksies en 
beperk baie van die aansteeklike komplikasies.  Vroeë diagnose en behandeling van XGA laat toe dat 
geaffekteerde individue ŉ relatiewe normale lewe ly. 
Doel:  Die doel van hierdie studie is om die molekulêre basis van XGA in Suid Afrika te ondersoek, deur 
gebruik te maak van direkte volgorde bepaling van die Btk geen in die hoop om die kliniese diagnose van 
die siekte aan te help. 
Metode : Manlike pasiente met ‘n kliniese diagnose wan XGA was by die studie ingesluit. Genetiese 
analise was gebruik om die “exonic” omgewing van die Btk geen te ondersoek van 5 onverwante manlike 
pasiente en vergelyk teenoor 10 gesonde kontrole. Waar moontlik was familie lede ogevolg om draers te 
bepaal. 
Resultaat:  Mutasies in die Btk geen is geidentifiseer in 3 van die 4 pasiente, klinies gediagnoseer meet 
XGA. Die mutasies sluit 2 reeds beskryfde variante in en een nuwe mutasie, ‘n een basis paar delesie in 
ekson 16 van die Btk geen,  Ten spyte van die kliniese profiel suggestief van XGA in die 5de pasient, was 
geen mutasies geidentifiseer in die “exconic” omgewing van die Btk geen nie, dit kan moontlik toegeskryf 
word aan die teenwoordigheid van ‘n ander vorm van PIGS in hierdie pasient.  Opvolg analise op die DNA 
van die moeders van die pasiente het die moederlike oorerwings patroon van die siekte bevestig aangesien 
al die moeders draers van die geidentifiseerde mutasie in die Btk geen van die gaffekteerde individu was. 
Gevolgtrekking:  Genetiese analise van die Btk geen blyk ŉ sensitiewe en spesefieke metode te wees om 
individue met XGA te diagnoseer. Hierdie studie ondersteun die gebruik van molekulêre metodes in die 
diagnose van PIGS en beklemtoon die moontlike sinergie wat kan bestaan tussen hierdie tipe benadering in 
die kliniese omgewing. 
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1. Background  
 
1.1 The immune system 
 
Throughout history, infections are known to be the most frequent cause of death [1]. The immune system 
functions to protect against these infectious complications by establishing ‘barriers’ or defence 
mechanisms. These defence mechanisms can be divided into two groups, namely innate and acquired (or 
adaptive) immunity (Table 1.1). Innate immunity can be defined as the host’s first line of defence and is 
present before the body is exposed to any infectious agents (antigens). Upon exposure, the innate system 
recognises a foreign organism and initiates a response by using macrophages to migrate towards the 
antigen, engulf and destroy it in a process called phagocytosis. Cells used in the initial response depend on 
where the antigen is detected. For example, if the antigen was detected in the skin, the Langerhans’ cells 
would be the first to migrate towards it, similarly, Kupffer cells in the liver, osteoclasts in bone and 
peritoneal macrophages in the intestine mediate the phagocytic response in other tissues. Besides their 
primary function of destroying foreign organisms, macrophages are responsible for the synthesis and 
release of chemokines and cytokines. These are chemical messengers that recruit other cells to the affected 
area. Some of the recruited cells include polymorphonuclear neutrophils (or monocytes), basophils, 
eosinophils and natural killer cells which all function in the successful eradication of the foreign organisms. 
Other molecules known as Complement are a collection of proteins in the blood that fight against bacterial 
infection. As its name suggests it complements and forms part of the innate immune system. [2]. 
 
It is important to note that innate immunity is, however, not antigen-specific and has no memory cells 
which respond quicker to antigens that have previously entered the host.  Acquired immunity however, is 
both antigen-specific and it has memory cells. It incorporates the use of specialised cells called B (bone 
marrow) and T (Thymus) lymphocytes. These cells only recognise specific antigens via B cell receptors 
(BCR) and T cell receptors (TCR) which are exposed on the surface of the B and T cells respectively. B 
cell response to pathogens is triggered when innate immunity fails to contain the invasion of infectious 
agent. i.e. some evolved microorganisms are able to inactivate phagocytic cells and thus would require the 
help of the host adaptive immunity for fighting the infection. T cells, respond to intracellular infections and 
are subdivided into T Helper (TH) cells and Cytotoxic T (Tc) cells. TH help B cells to  make antibodies and 
also activate macrophages to eliminate intracellular parasites. Tc cells eradicate the invasion by viral 
infections. Thus, acquired immunity is more specific and effective in its eradication of pathogens [2]. It is 
important to note that the immune system is not always successful in protecting the host from infectious 
complications and this can be attributed to a defect known as immunodeficiency. 
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1.1.1  Immunodeficiency 
 
Immunodeficiency (or immune deficiency) affects the hosts’ ability to fight against infection. An individual 
with a defective immune system is said to be immunocompromised. These individuals are categorized into 
two groups depending on how the immunodeficiency is obtained.  Most immunodeficiency states are due to 
acquired (or secondary) causes e.g  Acquired Immune Deficiency Syndrome (AIDS), tuberculosis, 
leukemia or more commonly to malnutrition, aging and sometimes specific medication [2]. A smaller 
number of immunocompromised individuals are grouped under Primary immunodeficiency disorders 
(PID). This type of immunodecifiency is congenital, usually due to genetic defect in the host’s defense 
mechanism. 
 
PID disrupts the proper functioning of the immune system [3]. This disruption is caused by mutation in 
genes, which are involved in the expression of components required for proper immune functioning [4, 5]. 
Research within the PID field has led to the classification of over 150 PIDs and more than 120 have been 
characterised genetically [6,7]. Most PIDs are characterized by the individual’s susceptibility to 
opportunistic organisms. These infections are usually persistent or recurrent regardless of aggressive 
treatment and affected individuals often have poor growth and fail to thrive. [3]. Onset of symptoms is 
usually in early infancy with 70% younger than 20 years old and 60% occurring in males due to the X-
linked manner in which many syndromes are inherited [8]. Classification of PIDs are based on the 
component of the immune system that is disrupted. 
 
For example, humoral immunity disorders affect B cells and antibody production which predisposes 
individuals to increased susceptibility for bacterial infections, whilst patients with cellular immunity 
disorders, due to T cell defects, are more prone to fungal, viral and parasitic infections [4, 5]. Similarly, 
phagocytic defects characteristically cause oral and skin infections and granuloma formations [5]. The most 
frequently diagnosed and treated PID is the primary humoral immunodeficiencies, more specifically, the 
antibody deficiency syndromes. These syndromes result from genetic abnormalities in genes involved in B 
cell development and are characterized by the individual’s inability to produce adequate amounts of 
Table 1.1 Components of the immune system 
 
Immunity Innate  Acquired 
Cells Phagocytes B cells 
  Monocyctes T cells 
  Basophils   
  Eosinophils   
  Natural Killer (NK)   
Molecules Cytokines  Cytokines  
  Chemokines Antibodies 
  Complement   
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circulating antibodies (Table 1.2), increasing their susceptibility for bacterial infections [9-11]. The clinical 
characteristics of antibody deficiency syndromes are similar with a marked reduction  in all serum Ig 
isotypes, however the underlying genetic mechanisms differ. The prototypic congenitally inherited antibody 
deficiency syndrome is X-linked Agammaglobulinemia [10]. 
 
 Table 1.2 Antibody deficiency syndromes 
 
Disease Inheritance Affected gene Affected Serum Ig  
B cell linker protein 
(BLNK) deficiency 
Autosomal Recessive BLNK All isotypes  
X-linked 
Agammaglobulinemia 
(XLA) 
X-linked 
Bruton Tyrosine 
Kinase (Btk) 
All isotypes  
Igα deficiency Autosomal Recessive Igα All isotypes  
Igß deficiency Autosomal Recessive Igß All isotypes  
μ heavy chain deficiency Autosomal Recessive μ heavy chain All isotypes  
λ5 deficiency Autosomal Recessive IGLL1 (λ5) All isotypes  
 
 
BLNK: B cell linker protein; α : alpha; ß : beta; μ: mu ; λ: lambda; () decrease 
 
1.2 X-linked agammaglobulinemia 
 
X-linked Agammaglobulinemia (XLA), also known as Bruton’s disease, is the prototypic PID and was first 
reported and defined by O.C Bruton in 1952. XLA is inherited in an X-linked recessive manner and affects 
approximately 1 in 200 000 individuals [12]. Males are almost exclusively affected, whereas carrier 
females, having both the normal and mutant allele appear immunologically normal. Transmission of the 
mutant allele to the progeny however, will result in the development of XLA in males and a heterozygous 
genotype in females [13,14]. During the first 9-12 months after birth the condition goes undetected as the 
male infant is protected by transplacentally acquired maternal immunoglobulin (Ig) G. As these levels 
decrease physiologically without compensatory production of the infant’s own immunoglobulin, the infant 
becomes extremely vulnerable to recurrent infections (mainly caused by encapsulated bacteria). Most 
infections are due to pyogenic bacteria and the most common sites of infections include the lower 
respiratory tract, middle ear and sinuses [3, 15].The greatest threat to aggammaglobulinemia patients are 
enteroviral infections which can result in chronic meningoencephalitis [16, 17]. Common organisms found 
in enteric infection are Giardia lamblia, Campylobacter jejuni and Salmonella spp. Common respiratory 
pathogens that lead to infection, are Streptococcus pyogens, Heaemophilus influenzae and Bordetella 
pertussis ([3], Table 1.3).  Lack of antibody supplementation and immunoglobulin (Ig) replacement 
treatment leads to chronic obstructive pulmonary disease and premature death. T cell function appears 
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normal and therefore normal resistance is present against viruses and fungi, with the exception of 
enteroviruses and hepatitis [18, 19].  
 
 
Table 1.3 Infection and common pathogens in X-linked Agammaglobulinemia 
 
Recurrent Infections  Upper and Lower Respiratory tract infection  
  Sinusitis 
  Otitis 
  Skin lesions 
Major Infections Pneumonia 
  Septicaemia 
  Meningitis 
Common Pathogens Giardia lamblia 
  Campylobacter jejuni  
  Salmonella spp 
  Streptococcus pyogens 
  Heaemophilus influenzae 
   Bordetella pertussis 
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1.3  Treatment 
1.3.1 Intravenous Immunoglobulin (IVIg) treatment 
 
For XLA patients to live a near normal life, appropriate treatment must be given. Intravenous 
gammaglobulin replacement therapy (IVIg) is the standard of care for XLA, which provides passive 
immunity reducing the number and severity of infections as well as limiting many of the infective 
complications. Thus, early detection and appropriate intervention of XLA, increases the patient’s lifespan 
and can allow the XLA-affected individual to live a relatively healthy life. 
 
IVIg, is a cold alcohol fractionation, pooled from thousands of human blood donations [12]. IVIg is infused 
at 3-4 week intervals, for the duration of life. The dose is dependent on the trough levels of 
immunoglobulin and clinical symptoms of the patient. Thus an increase of infective problems may need  
more frequent infusions. Infusion side-effects include nausea, headaches, flushing, myalgia and vomiting 
[12, 20]. Home administration is possible in the case of older patients on a regular regime for convenience.  
 
 
1.3.2  Alternative immunoglobulin treatment 
 
Subcutaneous treatment literally means ‘under the skin’ treatment. Subcutaneous immunoglobulin (SCIg) 
is an alternative approach that involves use of intramuscular preparations of gammaglobulins and is usually 
recommended to patients who have adverse reactions to the IVIg treatment and for more even trough 
levels. This approach of administration is also sometimes preferred in the pediatric population as venous 
access in infants is exceptionally difficult [21]. The disadvantage, however, is that there is an increase in 
the frequency of infusion, as only a limited volume of Ig can be administered per infusion [12]. A study 
done by Quartier et al. revealed that the initiation of immunoglobulin replacement therapy early in life 
(within 3 months of diagnosis)  significantly improved the patients wellbeing. It resulted in a drastic 
reduction in infectious problems and prevented severe, life-threatening bacterial infection and pulmonary 
complications [22].  
 
It is important to note that none of these treatments are the cure for XLA, as currently available treatment 
only provides passive immunity, reducing the number and severity of infections as well as limiting many of 
the infective complications. It is therefore important that patients are monitored on a regular basis (every 3 
months) regardless of the excellent clinical response of most patients, to ensure that optimal levels 
(recommended replacement dosage : ~0.4 – 0.6gm/kg every 3-4 weeks ) are being maintained. 
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1.4 Bruton tyrosine kinase (Btk) gene 
 
In 1993, two different research groups discovered that the disorder known as XLA, is caused by a mutation 
in the Bruton tyrosine kinase (Btk) gene [23, 24]. Mutation in the Btk gene results in an arrest in B cell 
development and almost an entire absence of serum immunoglobulin [10, 25]. 
 
1.4.1 Structural organization of the Btk gene 
 
The structural organization of the Btk gene was determined using “positional cloning” strategies as well as 
a reverse genetic approach [23, 24].  It was mapped to the long arm of the X chromosome in the region of 
Xq21.3-Xq22 [26] and consists of 19 exons that extend over 37kb of genomic DNA [26]. The protein 
product is 77kD in weight and comprises of 659 amino acids [23,24].  
 
This gene encodes for the Btk protein which consists of five structural domains (Figure 1.1). Proximal to 
the N-terminus is the Pleckstrin homology (PH) domain. This domain is the activation site of the Btk gene, 
and is followed by the proline-rich Tec homology (TH) domain [27], the Src homology 3 (SH3) domain, 
Src homology 2 (SH2) domain, and the catalytic kinase (also known as Src  homology 1) domain. All are 
involved in protein-protein interaction except for the kinase domain [19]. Even with the vast amount of 
information, gained over the past few years, the exact mechanism(s) that results in Btk activation and the 
principal phosphorylation is yet to be established. Understanding the crystal structure of the Btk protein 
contributes to the structural comprehension of how mutations disturb the proper functioning of the Btk gene 
and subsequent XLA disorder. Crystal structures provide a more comprehensive view of interactions than 
other models. And thus understanding the protein at a structural level will provide better insight into how 
mutations within the Btk gene (genotype) leads to different ‘physical manifestations’ of the XLA disorder 
(phenotype) [28]. Mutation distribution within the 5 domains is approximately proportional to the length of 
the domain, with the exception of the TH domain [29]. 
 
These (variable) domains are frequently found in signalling proteins [30], other than the Btk gene and (the 
proteins) are involved in a multitude of cellular interactions with cell surface receptors, transcription 
factors, signal transduction and more [19]. In order to better understand properties and functions of the Btk 
gene and these other proteins, focus has been shifted to the domains involved as knowledge of the function 
of one domain in one protein may reveal the functioning in many other proteins carrying the same domain 
[30,31]. 
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Figure 1.1  The alignment of exon 1 - 19 in the various domains [left] (showing the N-terminal PH domain (red), TH 
domain (blue), SH3 domain (green), SH2 (pink) and the kinase domain (light blue). Intronic regions are represented by 
the solid straight lines between exons) and the location of the Btk gene in the X-chromosome [left].Phosphorylation 
regiouns (pY223 and pY551) are also indicated on the figure, and play an important role in the activation of Btk. 
Adapted from : [32] and Genetic Home Reference. (1993).  (Accessed : September 27, 2010 at : 
http://ghr.nlm.nih.gov/gene/BTK) 
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1.4.2 Btk and B cell development 
 
The Btk gene is mainly expressed in cells of the lymphoid and myelomonocytic lineages and is crucial for 
B cell development, growth regulation and differentiation [16,23,24]. Btk expression allows for normal B 
cell development which leads to the expression of functional light and heavy chain genes and thus normal 
B cell lineage. Antigenic stimulation of the B cells ultimately leads to the making of plasma cells which 
produce specific antibodies, with the assistance from T cells [16].    
 
Most individuals with the XLA disorder have normal amounts of progenitor (pro-) and precursor (pre-) B 
cells in their bone marrow, but few or no mature B cells in their peripheral circulation [16, 34]. Whilst pre-
B cells express Ig heavy chains they do not express the light chains [16, 35]. Due to the Btk-deficiency B 
lymphocytes functional light genes are not expressed in XLA patients, and thus mature B cells do not 
develop (Figure 1.3).  This block results in B cell immunodeficiency which predominantly affects antibody 
production. Low or absent mature B lymphocytes in the periphery (peripheral circulation) and lymph node 
germinal centers leads to a severe reduction of serum immunoglobulins (Ig) levels of all isotypes [19, 33]. 
These individuals are therefore more susceptible to recurrent bacterial infection because of their lack of 
immunoglobulin production. The defect appears to be specific to the B-cell lineage as other lymphocyte 
populations (i.e. T cells) are not affected [16,17]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Blockage in the B cell development. B cell production is arrested  
at stages between pro-B and pre-B cells which results in B cell apoptosis and 
 the subsequent XLA phenotype.[Adapted from Ref. 30]. 
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1.4.3 Btk activation and function 
 
Btk is dependent on its association with various ‘partners’ for its activation and regulation.  
 
Btk activation is initiated by antigen stimulation of BCR on mature B cells, which induces tyrosine 
phosphorylation of Btk [36]. This partially activates Btk and places it in the BCR signal transduction 
pathway which reiterates the essential role of Btk in driving B cell differentiation. BCR-crosslinking 
ultimately leads to PH domain-mediated translocation of Btk to the plasma membrane [37], where it is 
further phosphorylated at Y551 by Src family kinase, either lyn or fyn. This phosporylation increases the 
proteins activation considerably [36] and also leads to the subsequent autophosphorylation event involving 
the Y223 of the SH3 domain which results in the full activation of Btk [36, 38] . Btk is primarily found in 
the cytosol with small amounts in the plasma membrane fraction. This suggests that most of Btk function is 
exercised in the cytosol. [39]. Activated Btk recruits B cell linker (BLNK) protein and phospholipase C-
gamma-2 (PLC-  2) to the plasma membrane. Btk and BLNK interaction contributes to the complete 
tyrosine phosphorylation of PLC-  2 [40] and the succeeding PLC-  2 phosphorylation ignites the 
downstream signal pathway which provides the platform for a variety of signal proteins [39]. 
 
Several studies have shown that a defective Btk gene results in an ‘autonomous B cell lineage defect’ 
[12,16, 34, 41]. This affects pro-B cells ability to thrive, reduces the pre-B cell proliferation [42] and also 
results in low to no numbers of B cell in the peripheral blood. Apart from Btk’s crucial role in B cell 
development [43]  Btk also has a role in intracellular calcium concentration in response to antigen receptor 
stimulation as it sustains low levels of intracellular Ca2+, required for proliferative responses of B cells. In 
this way it provides protection from bacterial infection. Btk has also been implicated in regulation of 
transcriptional factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-кB). NF-
кB plays a role in regulation of immune responses to infections and is involved in a cellular response to 
stimuli such as cytokines as well as bacterial infection [44, 45]. This implicates the kinase in a role that 
involves the functioning of immune cells of innate as well as adaptive immunity [46, 47].  
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1.4.4 Types of mutations found in the Btk gene 
 
Mutations are distributed along all five functional domains, almost evenly throughout the gene, however, 
studies show that they tend to group at the tyrosine kinase domain (Table 1.4, [48, 49]). There are several 
types of mutations that leads to disease-causing XLA. Namely, single base pair substitutions that result in 
amino acid substitution, splice defects, premature stop codons as a result of nonsense mutations as well as 
small insertions and deletions that result in frameshift mutations. These mutations are found in both the 
coding (exonic) and non-coding (intronic) region of the Btk gene however most disease-causing mutations 
are found in the exonic region. Having effects on the protein expression, stability, activity as well as other 
properties of the protein [13]. Several DNA analysis studies done by several groups have found that 
approximately one-third of human Btk mutation causes amino acid substitution [13,17, 50-52] which 
results in unstable proteins, but normal amounts of Btk mRNA [18, 51]. Analysis of Btk expression in XLA 
patients revealed that regardless of the mutation type, most of these individuals did not express the protein, 
others led to a truncated protein [13, 53]. Mutations are mostly found in the coding region and over 12% of 
mutations have been found to interrupt on splice site recognition sequences [13]. Mutations usually affect 
conserved residues and functionally significant regions, causing alterations to the protein [13, 54]. The 
effect of some genetic variations are however better tolerated than others and clinical severity can usually 
be ascribed to the type and location of the mutations [55]. 
 
It is no surprise that drastic changes in protein properties are likely to have a drastic effect on its 
functioning. A database for XLA, was founded in 1994, as the first immunodeficiency mutation database 
(IDbase). The BTKbase Mutation registry for XLA Version 8.5 (last updated 21 August 2008) has a large 
collection of comprehensively, described Btk mutations that result in the XLA disorder and also contains 
clinical information of patients [29] This database can be accessed in the XLA mutation registry at: 
http://bioinf.uta.fi/btkbase/ [59]. 
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Figure 1.3 Mutation distributions in the 5 domains 
- Mutations appear to be evenly spread throughout all structural domains except SH3domain. 
-  Mutation distribution also correlates to the length of the domain. 
 Pleckstrin homology  (PH) domain; Tec homology (TH) domain ; Src homology 3 (SH3) domain;  
 Src homology 2 (SH2) domain  
 
 
 
1.5 XLA diagnosis in South Africa 
 
There is still a considerable amount of diagnostic delay despite available treatment. This is mainly due to a 
lack of awareness of PID (in the less established or under privileged communities) and due to lack of 
appropriate diagnosis. 
 
 
1.5.1 Diagnostic testing 
 
At present, XLA in South Africa is mainly diagnosed using clinical and immunological parameters such as 
recurrent (severe) infection, low to no serum immunoglobulin levels, no CD19+ B cells and a family history 
[3,10, 11, 43]. One third of XLA cases occur sporadically [17] and in these cases a clinical and 
immunological diagnosis is not sufficient. The seemingly low prevalence of XLA in S.A could be due to 
the fact that the clinical parameters used to diagnose XLA is similar to that of the Common Variable 
Immunodeficiency disorder (CVID) [60], resulting in XLA patients being misdiagnosed. Another 
possibility is that the severely affected infants may not survive long enough for diagnosis or intervention. 
 
This study does not dismiss the value of clinical and immunological features as a useful method of 
diagnosing XLA but rather emphasises the importance of adjunct genetic confirmation. An extensive 
genetic Btk analysis on Agammaglobulinemia patients will allow for the identification of mutations within 
the Btk gene which would confirm XLA status within patients. Sequence-based diagnosis provides a 
definitive, convenient method that can be used in routine XLA genetic diagnostics, to support clinical 
diagnosis of patients without family history of XLA. Majority of patients have significantly reduced B cells 
and Ig levels. Thus another form of diagnosis is by monitoring the number  of CD19+ and CD20+ B cells, 
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IgG, IgM and IgA levels which are usually reduced in an XLA patient. Table 1.4 shows the clinical, 
immunological and genetic diagnosis required for an accurate diagnosis of XLA.  
 
 
 
 
 
 
 
1.5.2  Diagnostic test benefits 
The implementation of an XLA diagnostic screen test will allow physicians to promptly provide adequate 
clinical treatment plans and interventions. It will also allow for patient and family screening with diagnosis 
of XLA. Early recognition will lead to early treatment, appropriate medical follow-up and hopefully 
prevention of complications of the affected individual. 
 
 The clinical data from the affected XLA patients of this study, are recorded in our Primary 
Immunodeficiency South Africa (PISA) Registry, which is a Registry for PIDs in South Africa. The 
registry and our study are part of an effort to improve awareness of PID in S.A and for early diagnosis and 
better patient care.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.4 Diagnostic Testing of XLA 
Clinical Diagnosis 
a.   Male patient 
b.   Recurrent bacterial infections in the first two years      
      of life. 
c.   Btk mutation presumed 
Immunological Diagnosis 
a.   < 2% of CD19 positive B cells in the blood 
b.   Low Serum concentration of IgA, IgG and IgM  
            (more than 2SD below the mean for age) 
Genetic  Diagnosis          a.   Mutation in the Btk gene  
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1.6 Research design and methodology 
 
This research was conducted to identify abnormalities in the Btk gene of patients, clinically diagnosed with 
XLA. Molecular diagnosis coupled to clinical history of the patient provides a definitive XLA diagnosis. 
The research focused on five unrelated individuals and their available family members. They were selected 
primarily from the Primary Immunodeficiency South Africa Registry. In an attempt to investigate XLA in 
South Africa, a call was sent out to doctors throughout S.A (Appendix A) but the response was poor and 
thus the study was limited to 5 male patients. Figure 1 presents a flow chart of the process undertaken in 
this study. 
 
The inclusion criteria for this study were a clinical diagnosis of XLA compared to a group of healthy 
‘negative’ controls. Each participant provided informed consent and a blood sample. DNA is subsequently 
extracted from the blood and all 19 exons of the Btk gene are analyzed using PCR techniques. After 
amplifying all 19 exons individually  for each patient, the PCR product is purified using a Wizard® SV Gel 
and PCR Clean-up System kit standard procedures (Promega, Maddison USA), sequence reactions are 
carried out using a BigDye Terminator Cycle Sequence Kit (Applied Biosystems, Foster City USA) and 
assembled to the Btk reference sequence (Accession: U78027) using BioEdit. Once the mutation was 
identified, mothers of the patients were tested using a mutation-specific test to identify maternal carrier 
status. Mutations are also compared to those found on the online Btk database in order to further classify 
mutations as known or novel.  
 
 
 
 
             
         
                                    
 
 
 
 
 
 
 
 
 
 
 Figure 1.4 Research plan of action 
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Abstract :  
X-linked agammaglobulinemia (XLA) also known as Bruton’s Disease, the commonest primary 
immunodeficiency syndrome, results from Bruton tyrosine kinase (Btk) gene mutations. Affected patients 
fail to generate mature B cells and are unable  to produce antibodies. Diagnosis is frequently delayed until 
onset of severe and recurrent infections. Early diagnosis by genetic studies can prevent morbidity and 
mortality. With DNA based PCR we investigated unrelated male patients, with a clinical diagnosis of XLA. 
We recorded three different mutations, one of which was novel. This method proved to be efficient for the 
detection of Btk mutations providing a definitive diagnosis for patients and carriers in South Africa. 
 
Keywords : Primary Immunodeficiency (PID), X-linked agammaglobulinemia (XLA), Bruton tyrosine kinase (Btk), 
Polymerase chain reaction (PCR). 
Introduction 
 
Primary immunodeficiency disorders (PID) disrupt the proper functioning of the immune system [1]. This 
is caused by mutation in genes, required for proper immune functioning [2,3]. The prototype PID is X-
linked agammaglobulinemia (XLA), which was reported in 1952, by O.C Bruton [4]. The patients are 
usually male, have less than 2% CD19+ B cells in their peripheral blood and subsequently lack humoral 
immune responses. Deficient antibody production of all immunoglobulin isotypes results in an excessive 
susceptibility to infections. It was later discovered, that this disorder is caused by a mutation in the 
cytoplasmic tyrosine kinase gene known as Bruton’s tyrosine kinase (Btk) [5,6]. The Btk gene is mapped to 
the long arm of the X chromosome in the region of Xq21.3-Xq22 [7] and consists of 19 exons that extend 
over 37.5 kb of genomic DNA [8]. The protein product is 76kD in weight and consists of 659 amino acids 
[5,6]. The Btk gene has five functional domains. Proximal to the N-terminus is the Pleckstrin homology 
(PH) domain, followed by the Tec homology (TH) domain, Src homology 3 (SH3) domain, Src homology 2 
(SH2) domain and the catalytic kinase domain (Figure 1). Mutation distribution within the 5 domains is 
approximately proportional to the length of the domain with the exception of the TH domain [9]. 
 
 
 
 
 
The Btk gene is mainly expressed in cells of the lymphoid and myelomonocytic lineages and is crucial for 
B cell development, growth, regulation and differentiation [5,6,10]. Mutations result in an arrest in B cell 
development due to complete block in B cell development (Figure 2). This predominantly affects antibody 
production with low or absent immunoglobulin levels and lack of lymph node germinal centers, [11,12]. 
The defect appears to be specific to the B-cell lineage as other lymphocyte populations (i.e. T cells) are not 
affected [13]. 
 
                                                            
 
 
 
 
 
Figure 1. The domain structure of the Bruton’s Tyrosine kinase protein. 
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The severity of XLA varies with each individual, even relatives that share the same mutation differ in their 
clinical phenotype [14,15]. The most common clinical and immunological features include recurrent 
infections especially with bacteria (Table I ) and very low B cells and immunoglobulins. The standard 
treatment for XLA is intravenous gammaglobulin replacement therapy (IVIg), which provides passive 
immunity thereby, reducing the number and severity of infections as well as many of subsequent 
complications. Diagnostic delay is still common however and this may be due to a lack of availability of 
screening tests and lack of awareness of PID in especially the less privileged communities. Nevertheless, 
the XLA is suspected in males with early onset, recurrent bacterial infection, a marked reduction in B cell 
numbers (< 2 % CD 19+ B cells) with low to no detectable levels of serum immunoglobulin upon clinical 
and /or immunological investigation [1,4,11,16]. A definitive diagnosis is confirmed only in individuals 
who have genetic analysis and who are identified with a mutation in their Btk gene [17]. Genetic testing is 
also the most reliable way of identifying female carriers of XLA. Carrier testing should be offered to 
females who have a family history of XLA.  
 
 
 
                                                 Table I Clinical Presentation of XLA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A registry containing mutations and phenotypes for XLA was founded in 1994, and was the first 
immunodeficiency mutation database (IDbase) (BTKbase : http://bioinf.uta.fi/btkbase/). It contains 
mutation entries for over 1000 patients from more than 900 unrelated families, representing more than 600 
unique molecular events [9,18]. In this study we performed genetic analysis on a group of 5 male unrelated 
patients with a clinical diagnosis of XLA. Polymerase chain reaction (PCR)-based method was used for 
detection of mutation in the Btk gene and subsequent XLA diagnosis. 
 
 
Method 
 
The screening approach used to characterize the mutations identified in the Btk gene of the XLA patients 
was DNA-based PCR method, using 38 primers (Appendix C, [19]) to amplify all 19 exons of the Btk 
gene, followed by direct sequencing and subsequent sequence analysis of the Btk gene. Mutational analysis 
was performed on five male patients from five unrelated families, four of the patients had an XLA 
compatible phenotype. The remaining patient presented with recurrent infection and a phenotype similar to 
XLA, however did not fit the strict criteria for a clinical diagnosis of XLA. His participation in the study 
served as a negative-diseased control with hypogammaglobulinemia. Two patients included in this study 
receive care at our clinics at Tygerberg hospital. The remaining three were refered to by physicians from 
different instituitions. Table II shows the laboratory data of the 5 unrelated patients.  
Recurrent Infections 
• Otitis 
• Sinusitis 
• Conjunctivitis 
• Rhinitis 
• Pneumonia 
• Arthritis 
Most common infectious agents  
• Streptococcus 
• Pneumoccus 
• Staphylococcus 
• Giardia 
• Echovirus
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Table II  Relevant Immunological data at diagnosis 
 
Patient No. 001 002 003 004 005 
Ethnicity  White White  Coloured White Black 
Age at 
diagnosis 4yr 1yr 3months 3months 7yr 3months 7yr 9months 
Serum Ig Levels (g/L) *
IgG 1.09 0.1  0.33  0.33  <1.41  
IgM 0.2 0.02  0.1 0.08  <0.25  
IgA 0.07 0.06  0.07  0.07 1.09 N 
B cell enumerations (%)
CD19+ <2% 0% 0% 1% 1% 
 
* Serum Immunoglobulin level and B cell number reported at the time of diagnosis.  
Reference ranges from Ref 16. 
 Low 
N Normal 
 
Patient 003 had a family history of XLA and was previously reported on by Pienaar et al. [20], he was 
included as a positive control. Female carrier detection was done when possible, this included the mother  
and sibling of Patient 001 and the mother of Patient 002. Ten healthy individuals with various ethnicities 
were included as negative controls. The initial step involved the preparation of DNA from (EDTA-lined) 
blood followed by the amplification of the 19 exons in the Btk gene using PCR method. PCR products were 
then directly sequenced and in a final step mutation analysis was performed in the 5 unrelated patients. 
Ethical clearance was obtained from the Ethics Committee for Human Research at Stellenbosch University 
and written consent was obtained for each participating individual. 
 
Results 
PCR analysis followed by direct sequencing analysis revealed three different mutations (Figure 3). Two 
mutations were previously described [20-22] and one novel mutation was identified. Mutations were 
observed in the PH, SH2 and Kinase domain. Two XLA causing mutations identified within the Btk gene 
were located in the Pleckstrin-homology (PH) domain . The Btk mutational analysis of Patient 001, 
revealed a mutation at the amino acid position 28  (R28H) resulting in a missense mutation in exon 2 which 
is consistent with the classical diagnosis of XLA. This amino acid change was first identified by de Weer et 
al. [21] and the BTKbase contains 17 patients with the R28H mutation 
(http://bioinf.uta.fi/BTKbase/index.php?content=index/IDbases). The second Btk mutation (in Patient 003 ) 
found in the PH domain was identified by Pienaar et al. (2000), a Δ 60 mutation of the Btk gene as a AAG 
deletion found at amino acid positions 308-310, which results in the loss of a single amino acid, lysine at 
codon 60. The BTKbase contains 7 patients with the K60del mutation, six of the patients were collected 
from the study done by Pienaar et al. the 7th patient was reported in 2003 by a study done in Argentina [23]. 
Patient 002 had a point mutation in the SH2 domain of the Btk gene which results in a C-to-T change at 
position 862 in exon 10 of the Btk gene. This mutation has been reported in 29 other unrelated families [21] 
and can also be found in the Btkbase. 
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Figure 3. Schematic view of the sequence analysis of patient 001 (a), Patient 002 (b), 
Patient 003 – the positive control (c) and Patient 004 (d). Mutated Nucleotide is indicated with an arrow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mutation found in Patient 004 in the kinase domain appears to be a novel mutation as no published  
literature was found. This mutation has been submitted, to the website. Once the mutation has been 
validated the publication of the entry will appear in the next database released. Although Patient 005 did 
not conform to the strict criteria for clinical diagnosis of XLA with normal serum IgM levels, he was 
included in this study on the basis of his low levels of B cells, recurrent infections and similar phenotype to 
that of XLA patients. His inclusion served as a negative-disease control and was thus not expected to have 
a detectable Btk gene mutation,  this was confirmed on mutation analysis of his Btk gene. Table III 
summarizes the mutations identified and also indicates whether or not relatives were affected. Two  
mothers and one other family member were available for evaluation in this study. Screening the sequence 
of Patient 001’s mother indicated that she was a carrier (heterozygous) of the mutation. Although the 
mother of Patient 001 had no desire of having any more children and therefore declined the offer to speak 
to a genetic counsellor she did however wish for her daughter, the twin of Patient 001 to be tested as well. 
She too was a carrier of the mutation. Patient 002’s mother was tested in the same manner and her results 
indicated that she was also a carrier affected by XLA mutation found in Patient 002. As for the mother of 
Patient 003 she was previously documented to have the Btk mutation identified in Patient 003 and her 
participation in this study was useful as a positive carrier control. Detected mutations were described 
according to den Dunnen and Antonarakis [24] using the Btk cDNA sequence as reference sequence 
(GeneBank accession   number NM_000061.1) in which the A of the ATG translation ‘initiates’ the start 
site representing nucleotide +1[9, 24]. 
 
Table III. Characterisation of the mutations found in the Btk gene of unrelated XLA patients 
 
Patient 
No. Exon 
Btk 
domain Type of mutation 
Nucleotide 
position1,2 
Amino Acid 
Change2 
Affected 
relatives 
001 2 PH 1bp substitution c.83G>A p.R28H + 
002 10 SH2 1bp substitution c.862C>T p.R288W + 
003 3 PH 3bp deletion c.308-310delAAG p.K60del + 
004 16 Kinase 1bp deletion c.1629delC p.S543del N.D 
005 N.D N.D N.D N.D N.D N.D 
1Numbering of the nucleotide and amino acid positions refers to cDNA sequences (GeneBank accession   number 
NM_000061.1). A of the ATG translation initiates the start site representing nucleotide +1 [9,23] . Patients who had an 
affected relative are indicated with a (+). The novel mutation is indicated in bold. Patient 005 had no mutation in his 
Btk gene. (ND : Not determined). 
 
Del : deletion; In Bold : Novel mutation 
 30
Discussion  
 
This study explored the molecular diagnosis of unrelated XLA patients in South Africa. The method used 
was a DNA-based, to detect abnormalities in the Btk gene. Data represent three male patients identified 
with a Btk mutation. Two of the patients (P001, P002) had mutations previously described in the Btk 
mutation database (BTKbase) and one novel mutation was identified in Patient 4 (P004). Patient 005 
illustrates an XLA-like phenotype with a defect possibly in another gene required for proper B cell 
development for example µ-heavy chain or the λ5/14.1 genes. One study of three patients indicated that 
patients with mutation in µ-heavy chain, the λ5/14.1 and Btk gene all resulted in having impairment in 
differentiation from pro-B cell to pre-B cell [11]. Thus demonstrating that defects in any of these genes can 
result in similar clinical features. 
 
In South Africa, agammaglobulinaemia is currently diagnosed only according to clinical and basic 
immunological features. A definitive diagnosis of XLA without genetic analysis is possible in a patient 
with a family history of XLA. However one-third of XLA cases occur sporadically [25] and in these cases a 
clinical and immunological diagnosis is insufficient and commonly delayed. These patients especially 
require the addition of molecular diagnostics involving a specific Btk mutational analysis to provide a clear 
diagnosis. Though this study involved a limited number of patients, investigators believe that the results 
obtained will be of value and direct beneficial use for family members of the five patients. The study also 
aimed to increase awareness as well as providing accurate diagnosis of XLA. Using Btk mutational 
analysis the above mentioned knowledge can be applied to ensure early detection of Btk gene abnormalities 
of affected males and also carrier females. This will allow physicians to provide appropriate clinical 
treatment plans and early interventions for best prognosis and outcome. The clinical data from all patients 
are recorded in our Primary Immunodeficiency (PISA) Registry for PIDs in South Africa. The registry and 
studies such as this one aim to identify the prevalence of these genetic diseases in South Africa for 
appropriate diagnostics and treatment algorithms to improve patient care.  
 
Summary  
 
Mutational analysis led to a definitive diagnosis of XLA in 3 of the patients each were identified with a 
different Btk mutation. Direct DNA sequencing of the Btk gene revealed mutations on exon 2 of Patient 
001, exon 10 of Patient 002, Patient 003 had previously been diagnosed with XLA and served as a positive 
control . And a novel mutation in exon 16 of Patient 004. Patient 005 was not definitively diagnosed with 
XLA even though he demonstrated clinical features similar to that of patients with the XLA status. This 
study promotes awareness of PID and may encourage more specific genetic mutational analyses of other 
Primary Immune disorders in South Africa. 
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Abstract 
X-linked agammaglobulinemia (XLA) is a result of mutations in the Bruton tyrosine kinase (Btk) gene. 
Genetic analysis of the BTK gene was performed on a group of 4 unrelated male patients with a clinical 
diagnosis of XLA using a direct sequencing approach. Analysis revealed 3 different mutations in 3 of the 4 
patients, namely c.83G>A (p.R28H), c.862C>T (p.R288W), and a novel mutation, c.1629delC (p.S543del). 
Evaluation of 2 available mothers revealed x-linked carrier status in both of the mothers. This study 
supports the usage of genetic analysis as a specific and sensitive method for the possible detection of Btk 
mutation and definitive diagnoses of XLA in South Africa. 
Key Words: X-linked agammaglobulinemia (XLA), Bruton tyrosine kinase (Btk), Pleckstrin homology (PH) domain, 
Tec homology (TH) domain, Src homology 3 (SH3) domain, Src homology SH2 domain,  kinase  domain. 
 
Introduction 
X-linked Agammaglobulinemia (XLA, MIM # 300300) is a primary immunodeficiency disorder (PID), 
first defined and reported by O.C Bruton in 1952 [1]. The underlying genetic basis of the disease was later 
discovered to be caused by mutations in the Bruton tyrosine kinase (Btk) gene [2,3] mapped to the long arm 
of the X chromosome in the region of Xq21.3-Xq22 [4] and consists of 19 exons that extends over 37kb of 
genomic DNA [5]. The protein product is 77kD in weight and comprises of 659 amino acids [2,3]. The Btk 
gene consists of five structural domains, proximal to the N-terminus is the Pleckstrin homology (PH) 
domain, followed by the Tec homology (TH) domain, Src homology 3 (SH3) domain, SH2 domain, and the 
catalytic kinase (SH1) domain. All are involved in protein-protein interaction except for the kinase domain. 
[6]. Mutations are almost evenly distributed along all five functional domains; however, studies have 
shown that most mutations can be found in the tyrosine kinase domain [7, 8]. The severity of the disease is 
associated with the type and location of the mutations [9]. A database for XLA was founded in 1994, as the 
first immunodeficiency mutation database (IDbase). The BTKbase Mutation registry for XLA Version 8.5 
(last updated 21 August 2008) contains more than 900 different Btk mutations combined with clinical 
information associated with the mutations (http://bioinf.uta.fi/btkbase) [10, 11]. The aim of this study is to 
determine the molecular basis of XLA in South Africa using a direct sequence-based method to detect 
abnormalities in the Btk gene. Molecular diagnosis coupled to clinical history of the patient provides a 
definitive XLA diagnosis. 
 
 
 35
Materials and Method 
Sampling of patients 
Blood was obtained from four unrelated, clinically diagnosed XLA male patients, each with an XLA 
compatible phenotype, namely <2% circulating CD19+B cells, very low levels of all serum 
immunoglobulin isotypes and recurrent infection, together with ten healthy individuals as study controls 
and a fifth patient who served as a negative diseased-control. After the initial screening on the index cases, 
family members were followed up to determine carrier status, where possible. Ethical clearance was 
provided from the Ethics Committee for Human Research at Stellenbosch University and a consent form 
was obtained from each participating individual.  
 
Genomic DNA extraction, Primers and PCR assay 
Total genomic DNA from Ethylenediaminetetraacetic acid (EDTA) blood samples was extracted by using 
the QIAamp DNA Blood Mini Kit (Qiagen GmbH,Hilden,Germany), following the recommendations of 
the manufacturer. All 19 exons, of the Btk gene, were screened using exon-specific primers as previously 
described [12]. PCR amplification reactions consisted of: 1.00 mM MgCl2, 0.20 mM dNTP mix, 1x Taq 
Colourless PCR buffer, 0.02 U/μl Go Taq Polymerase (Promega, Maddison USA), 0.20 μM of each primer 
[12] and 100 ng template DNA. The total PCR amplification reactions were prepared to 25 μL for each 
sample. The amplification conditions used for exons 1, 2, 4-7 and 17-19 was as follow:  initial denaturation 
at 95°C for 5 min; 15 cycles of denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, and extension 
at 72°C for 30 sec, followed by 30 cycles of denaturation at 95ºC for 30sec, annealing at 55ºC for 30sec 
and extention at 72ºC for 30 sec; followed by a hold cycle at 4°C. The parameters for exons 3, 15 and 16 
were similar to the above with the exception of an touch-down annealing temperature of 55º for 15 cycles 
and a further 30 cycles at 50ºC. Amplification products were then visualized on 2.0% TBE agarose gels and 
the PCR amplicons varied in size from approximately 143-315bp. Product sizes were confirmed by running 
a 100bp ladder on either end of the gel.  
 
Mutational Analysis 
After all 19 exons were amplified, amplicons were sequenced with the Big Dye Terminator cycle 
Sequencing kit (Biosystems , Foster City, USA) using the same primers as that in the PCR method. 
Samples were finally processed on an ABI3700 capillary Sequencer (Foster City, USA) and sequence 
variations were confirmed by sequencing in the opposite direction. These mutations were annotated using 
recommended nomenclature described by den Dunnen and Antonarakis [13] using the Btk cDNA sequence 
as reference sequence (GeneBank accession number NM_000061.1) in which the A of the ATG translation 
‘initiates’ the start site representing nucleotide +1 [10, 13]. 
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Results and discussion 
This study used molecular techniques to definitively diagnose patients with XLA. Individuals were selected 
based on clinical and immunological parameters compatible with an XLA phenotype (Table 1).  
 
 
Table 1  Relevant Immunological data at diagnosis 
 
Patient No. 001 002 003 004 005 
Age at 
diagnosis 4yr 1yr 3months 3months 7yr 3months 7yr 9months 
Serum Ig Levels (g/L) * 
IgG 1.09 0.1  0.33  0.33  <1.41  
IgM 0.2 0.02  0.1 0.08  <0.25  
IgA 0.07 0.06  0.07  0.07 1.09 N 
B cell enumerations (%) 
CD19+ <2% 0% 0% 1% 1% 
* Serum Immunoglobulin level and B cell number reported at the time of diagnosis.  
Reference ranges from Ref 14. 
 Low 
N Normal 
 
After extensive Btk Analysis, mutations were identified in three of the four unrelated patients. The presence 
of the mutations detected was confirmed using bi-directional sequencing. Mutations were observed in the 
PH, SH2 and the Kinase domains. Table 2 provides a summary of the mutations identified, its affected 
domain and whether the mutation was found in any of the relatives screened. 
 
 
 
 
 
 
 
Two patients (Patient 001 and Patient 002) had Btk mutations in conserved residues (R28H and R288W). 
The R28H substitution identified in Patient 001 (Figure 1a) results in a GA transition. The R288W 
missense mutation identified in Patient 002 (Figure 1b) presented with a CT transition. Both of these 
mutations are well defined mutations and are known to lead to a classical XLA - causing phenotype [15,16] 
evident from the way in which the mutation disrupts the functionally important conserved residues of the 
Table 2. Characterisation of the mutation found in the Btk gene of unrelated XLA patients 
Patient 
No. Exon 
Btk 
domain Type of mutation 
Nucleotide 
position1,2 Amino Acid Change
2 Affected relatives 
001 2 PH 1bp substitution c.83G>A p.R28H + 
002 10 SH2 1bp substitution c.862C>T p.R288W + 
004 16 Kinase 1bp deletion c.1629delC p.S543del N.D 
005 N.D N.D N.D N.D N.D N.D 
1Numbering of the nucleotide and amino acid positions refers to cDNA sequences (GeneBank accession   number NM_000061.1). A 
 of the ATG translation initiates the start site representing nucleotide +1 [10,13]  Patients who had an affected relative is indicated 
with a (+). The novel mutation is indicated in bold. Patient 005 had no noticeable mutation in his Btk gene. (ND : Not determined). 
 
Del : deletion
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Btk gene which leads to an arrest in B cell development and ultimately a deficiency in the immune system 
[17,18], evident in both index cases. On review of available history and laboratory data, Patient 001 and 
Patient 002 presented with low CD 19+ B cell numbers and various infectious complications, consistent 
with the criteria for XLA diagnosis. Their infections raised suspicions of a primary immunodeficiency 
disorder, which was later confirmed when laboratory results of there serum B cells and serum 
immunoglobulins were also seen to be exceptionally low. The mutations identified in Patient 001 and 002 
are both been reported in 17 and 29 other unrelated families respectively, described in the BTKbase [11, 
(http://bioinf.uta.fi/BTKbase/index.php?content=index/IDbases)].  
 
The novel mutation identified in Patient 004 (Figure 1c) leads to a frameshift in the gene. Frameshift 
mutations are predicted to result in protein truncation that usually prevents the production of normal 
transcripts [19] which is evident in Patient 004. This single base pair deletion detected in exon 16 encodes 
for the kinase activity of Btk [18] domain, is found in the ß 9 strand [20] and is a phosphorylation site in the 
kinase domain. It also plays a role in regulation of the kinase [21].This mutation has been directly 
submitted, using the electronic submission form on the website. Once the mutation has been validated the 
publication of the entry will appear in the next database released. Identification of a Btk mutation in three 
of the patients allowed for a specific-mutation screen test that could be performed on mothers and siblings 
available for evaluation in this study.  The specific mutations were detected in two mothers and a female 
sibling available for screening, which confirmed their carrier status and the X-linked inheritance pattern of 
the disease. Patient 005’s inclusion served as a negative-diseased control and was thus not expected to have 
a detectable Btk gene mutation. Even though Patient 005 had no visible mutation in the coding region of 
the Btk gene, this study excluded screening of the non-coding regions (i.e. the promoter or intronic region) 
thus the possibility exists that the clinical phenotype observed in this patient could be due to variations in 
these areas or from a defect in another gene resulting in the same clinical features as that found in XLA 
patients [22,23]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic view of the sequence analysis of normal and variant sequence of Patient 001; c.83G>A 
(p.R28H)  (a), Patient 002; c.862C>T (p.R288W) (b) and Patient 003; c.1629delC (p.S543del) (c). Mutated 
Nucleotide is indicated with an arrow. 
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In recent years, publications have focused less on de novo mutations and more emphasis is being placed on 
structure-function relationships specifically focused on  possible genotype-phenotype correlation. The most 
recent breakthrough by Lee et al. [19] describes a correlation between genotype and the severity of the 
disease in terms of occurrence of severe infectious complications and the age of disease onset. Lee et al. 
classified patients according to their early onset clinical presentation, severity of infections and mutation 
type. Groups included those with severe mutations presenting with infectious complications at an early age 
and those who had a less severe mutation, presented later on in life with a less severe form of the disease. 
Lee et al. further notes, that though these findings are not absolute they do suggest that a ‘global’ genotype-
phenotype correlation for XLA does exist [19]. As we are only reporting on a small group of patients 
consisting of one novel mutation we cannot comment on a correlation between mutation and the severity of 
clinical phenotype. 
  
In conclusion, to our knowledge this is the first study in South Africa to report different Btk mutations in 
four unrelated South African patients clinically diagnosed with XLA.  Sequence-based diagnosis provided 
a definitive and accurate method that can be used in routine XLA molecular diagnostics. This would 
facilitate early diagnosis of patients without a family history of XLA and will allow for the immediate 
institution of life saving replacement therapy, the detection of carrier status in family members and genetic 
advice. This study emphasises the importance of genetic analysis as an adjunct to the basic screening of 
clinical and immunological features in patients investigated for XLA.  
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4. Discussion  
 
4.1 Molecular analysis and interpretation 
This study, included five male patients from five unrelated families, four of the patients had an XLA 
compatible phenotype. The remaining patient presented with recurrent infection and a phenotype similar to 
XLA, however did not fit the strict criteria for a clinical diagnosis of XLA. His participation in the study 
served as a negative-diseased control with hypogammaglobulinemia. These patients were screened for 
mutations in the Btk gene using direct sequencing. Mutations were identified in the PH, SH2 and the 
Kinase domain of the Btk gene. Two of the three mutations were previously described and reported in the 
BTKbase, whilst the fourth mutation appears to be novel. 
 
Two point mutations were found in conserved residues of the Btk gene [1]. Patient 001 had a missense 
mutation in the PH domain resulting in a GA transition in exon 2, which led to an amino acid change of 
an arginine to a histidine (R28H). The PH domain is a small signal transduction domain [2]. It plays a 
crucial  role in the translocation of Btk from the cytosol to the plasma membrane which is a critical step in 
the phosphorylation and activation of Btk [3, 4] and is also said to act as a membrane anchor as it binds to 
phosphoinositides [5, 6]. Most mutations located in the PH domain are located in the positively charged 
end of the molecule and is presumed to affect the binding site for phosphatidylinositol lipids [7, 8], 
therefore preventing Btk migration to the cell membrane (via the reduce in its affinity for inositol 
phosphates). 
 
The genetic defect in Patient 001was first described by de Weer et al. [9] and is located in the conserved 
Arg-28 residue. This residue plays an important role in binding potential ligands such as phospholipids [7, 
8], therefore the genetic defect in Patient 001 leads to drastic reduction in the binding activity of Btk [7]. 
The mutation found in Patient 002 is in the SH2 domain. This domian plays a role in growth, metabolism, 
gene transcription and mitogenesis [11]. It also has a role in signal transduction as it mediates the binding 
of tyrosine-phosphorylated peptide motifs to other molecules in the signal transduction pathway [12, 13]. 
The R288W mutation detected in Patient 002, substitutes a C  T at codon 288 in exon 10 of the Btk gene. 
This substitution replaces the large basic arginine (R) with a large sized aromatic tryptophan (W) (R228W) 
causing a disruption in proper ligand binding [13]. This leads to a 200 fold decrease in stability and peptide 
binding affinity of the SH2 domain with phosphotyrosine molecules [14]. 
 
The mutations identified in Patient 001 and 002 have been found in 17 and 29 other unrelated families, 
respectively in the BTKbase   (http://bioinf.uta.fi/BTKbase/index.php?content=index/IDbases). Both of 
these mutations are well defined and are known to lead to a classical XLA status. This is evident from the 
way the mutations disrupt the functionally important conserved residues of the Btk gene, which leads to an 
arrest in B cell development and ultimately a deficiency in the immune system. On review of available 
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history and laboratory data, of both Patient 001 and Patient 002, they presented with low CD 19+ B cell 
numbers and various infectious complications, consistent with the diagnostic criteria for XLA status. These 
infections raised suspicions of a primary immunodeficiency disorder, which was later confirmed when 
laboratory results of their serum B cells and serum immunoglobulins were also seen to be exceptionally 
low.  
 
A family history of Agammaglobulinemia prompted Patient 003 to be investigated at the early age of 3 
months after birth. Initial laboratory results did not meet the criteria for XLA diagnosis due to the presence 
of maternal antibodies. He was presumed to have an XLA mutation and genetic analysis confirmed this 
[15] IVIg treatment was started before the onset of any serious infections. The identification of the family 
specific mutation described by Pienaar et al, in this family was performed previously ([15], data not shown) 
and this patient served as a positive control during this study. High variability of clinical expression has 
been reported in case-to-case comparisons of patients even within a family, affected with the same 
mutation [16,17]. This was also evident within Patient 003’s family.  
 
The novel Btk mutation in Patient 004 is found in the kinase domain (also known as the Src Homology 
(SH1) domain).The mutation identified was a single base pair deletion of a C at position 1629 in exon 16 
which leads to a frameshift deletion in the amino acid serine. This novel mutation is found in the ß 9 strand 
[12] in a functionally important site of the kinase domain. Exon 16 encodes for the kinase activity of Btk 
[11] and S543 is a phosphorylation site which plays a role in regulation of the kinase [18]. Studies thus far, 
have noted that mutations identified in the kinase domain mostly leads to no detectable protein kinase 
activity, with different effects on the protein stability [19, 20].  The mutation found in Patient 004 leads to a 
stop codon (Appendix D) which produces a truncated protein. This leads an alteration, subsequently 
preventing the production of a normal transcript [21]. Evaluation of Patient 004’s clinical history and 
comparing it to the other patients it would seem to indicate that the mutation identified in Patient 004 is a 
severe mutation. This discrepancy however could be due to the late age of diagnosis and delay in treatment. 
Precise characterization of the novel mutation would require Btk expression analysis. This mutation has 
been directly submitted, using the electronic submission form on the website. Once the mutation has been 
validated the publication of the entry will appear in the next database released. 
 
It is well known that Btk mutations have been identified in all five domains with XLA-causing disorder in 
each. In our study, mutations were found in the PH domain which is known to be important for the 
translocation of Btk to the membrane [7], the SH2 domain which is significant for its interactions with 
signalling molecules [14] and lastly the Kinase domain which is essential for kinase activity and ATP 
binding [22]. Thus it is clear that each domain of the Btk protein is in some way functionally important and 
collectively contributes to the proper B cell development and ultimately a functioning immune system. 
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Despite the clinical appearance of XLA in our diseased – negative control, Patient 005 had no visible 
mutation in the coding region of the Btk gene and since this study excluded screening of the non-coding 
regions (i.e. the promoter or intronic region) the possibility exists that the clinical phenotype observed in 
this patient could be due to variations in these areas.  
 
Another possibility is that Patient 005 has an XLA-like phenotype which is due to mutations in genes other 
than the Btk gene, such as the µ-heavy chain or the λ5/14.1 genes [26]. These genes also play an important 
role in B cell development and thus mutations in one of these genes could lead to a failure of B cell 
production and eventually to agammaglobulinemia. One study indicated that studies of patients with 
mutation in µ-heavy chain, the λ5/14.1 and Btk gene all resulted in impairment in differentiation from pro-
B cell to pre-B cell, in all three patients [25]. Which allows us to conclude that defect in any of these genes 
will result in similar clinical features. 
4.2 Carrier detection and genetic counselling 
Identifying a Btk mutation in three of the patients provided a specific mutation screen, which was also used 
to analyse their relatives. Since XLA has a maternal inheritance pattern, the analysis was offered to the 
mothers to confirm carrier status. 
 
Females are not usually affected by XLA but those identified with the carrier status carry one diseased copy 
of the gene and one normal copy. If one of the two X-chromosomes carries a gene defect that is detrimental 
to proliferation or survival, all the cells of that lineage will demonstrate preferential inactivation of the 
mutated X-chromosome [27]. Males only have one X-chromosome and therefore show both the clinical and 
immunological results of abnormality. A carrier mother needs genetic counselling to understand the 
implications to her unborn offspring. Genetic counselling is a process by which a trained professional 
provides individuals and /or family with information on genetic disorders such as this and provides detailed 
explanation of the nature and implications of inheritance of the disorder in laymen’s terms to enable the 
family to make informed medical and personal decisions.  
 
Three mothers and one other female family member were available for evaluation in this study. The mother 
of Patient 001’s was identified as a carrier (heterozygous) of the mutation. Although the mother of Patient 
001 declined the offer to a genetic counsellor she did, however, request the testing of her daughter who was 
confirmed to be a carrier of the mutation. The daughter will be offered genetic counselling when she 
reaches child bearing age. Patient 002’s mother was also confirmed as a carrier of the XLA mutation found 
in Patient 002. The mother of Patient 003 was previously confirmed to be with the carrier status [15] and 
her participation in this study was useful as a positive carrier control (data not shown). None of the patients 
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had male siblings with ‘XLA symptoms’ and were therefore not included in this study. It is however 
important to note that any relative, specifically male, that could be at risk, should be evaluated as promptly 
as possible by using the family specific- mutation screen test (if available). 
 
4.3 Phenotype - genotype correlation 
 
In recent years, publications have focused less on de novo mutations and rather on structure-function 
relationships and a possible genotype - phenotype correlation relating to the specific site of mutation in the 
Btk gene and the affiliated XLA phenotype.  
 
Earlier studies attempted to determine a correlation between phenotype and genotype in 
Agammaglobulinemia patients with mutation in the Btk gene done was unsuccessful [24,28]. However two 
studies done by two independent research groups brought about significant insight. The study done by 
Broides et al. [29] was a breakthrough in understanding Btk activity, Btk mutation and the subsequent 
affects. And Lee et al. [21] also describes a correlation between genotype and the severity of the disease in 
terms of occurrence of severe infectious complications and the age of disease onset. Lee et al. classified 
patients according to their early onset clinical presentation, severity of infections and mutation type. 
Groups included those with severe mutations presented with infectious complications at an early age and 
those who had a less severe mutation, presented later on in life with a less severe form of the disease. Lee et 
al.further noted, that though these findings are not absolute they do suggest that a ‘global’ genotype - 
phenotype correlation for XLA [21]. 
 
The only common feature in all patients analysed is the severe reduction in the number of B cells. More 
precise understanding of the functional consequence of the Btk gene mutation has the potential of defined 
diagnostic categories that may lead to more specific individual treatment.  
Early diagnosis and specific treatment would prevent complications from infections and would sustain a 
good quality of life. This will be possible through the elucidation of the Btk genomic structure and 
comparative studies of clinical outcome.  
4.4 Value of the methodology 
 
Since the discovery of XLA [30] by O.C Bruton in 1952 a lot of information on XLA and the Btk gene has 
accumulated. In this study we focused on a molecular technique that proved to be less labour intensive than 
previous reported methods. We utilized sequence-based diagnosis to support clinical diagnosis of patients 
with no family history of XLA. This proved to be a definitive method of diagnosis of affected male status 
as well as carrier determination. Sequence-based diagnosis has clear advantages with respect to speed, 
reliability and convenience making it suitable for routine XLA genetic diagnostics.  
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Undiagnosed or late diagnosis of XLA is associated with severe recurrent infections and leads to morbidity 
and mortality. This is avoided with early detection, which will prompt the institution of life-saving 
treatment (Intravenous Immunoglobulin replacement therapy) for the management of XLA. Delay in 
diagnosis or sub-optimal IVIg treatment and a lack of proper follow up can still result in poor outcomes 
that could lead to chronic infections, organ damage and a failure to thrive. In contrast, early diagnosis 
before onset of recurrent infections and IVIg treatment including adjustments to the treatment plan results 
in improved outcomes increasing the patient’s lifespan and allows the XLA-affected individual to live a 
relatively healthy life. 
 
Currently, there is no routine diagnostic facility for patient or carrier detection of XLA, available within the 
National Health Laboratory Services (NHLS). The first report of XLA in S.A was done by Pienaar et al. 
[15]. No further studies relating to the genetics of the Btk gene or XLA in South African patients have been 
reported. This study aimed to expand on the genetic knowledge of unrelated XLA patients in S.A using the 
sequence-based method. The main advantage of this method is that it allows for the detection of specific 
Btk gene abnormalities that would confirm/diagnose an XLA status within patients. This is a rapid method 
that can be done as early in life, requires minimal training, can be done by any PCR competent lab 
technician and can be housed in any laboratory with the ‘appropriate’ instruments/ apparatus. Results can 
be obtained within as little as  seven working days in the case where the mutations are known and with a 
high reliability of both the test and instrument. Routine availability of this test would ensure early XLA 
diagnosis in South Africa and will allow the immediate institution of life saving replacement therapy in 
affected patients. As mutation detection provides the most definitive method of XLA diagnosis [31].  
 
 
At present however, XLA in South Africa is still diagnosed according to clinical and immunological 
features and is suspected in a patient with a positive family history. As most patients lack a positive family 
history clinical and immunological diagnosis is insufficient for early accurate diagnosis. These patients 
require molecular diagnostics involving a Btk mutational analysis to provide a clear diagnosis. Patients who 
present with atypical XLA and one-third of XLA cases that occur sporadically [32] will also benefit from 
molecular diagnosis. Another advantage of molecular XLA diagnosis is in the differentiation of XLA from 
Common Variable Immunodeficiency disorder (CVID). Although the clinical features are similar between 
XLA and CVID these disorders are  significantly different at the molecular level [33, 34]. This study aimed 
to develop a screening test screen test for the NHLS and will be validated, standardized and offered in the 
Pathology Research Facility (PRF) Laboratory, Tygerberg Campus, Stellenbosch University. Our long term 
goal is to encourage and motivate efforts for improved management of XLA and other PIDs in South 
Africa. A secondary aim of this study was to encourage further research in the PID genetic field of South 
Africa. 
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X-linked Agammaglobulinaemia Search  
BACKGROUND 
 
X-linked Agammaglobulinaemia (XLA) is a 
humoral immunodeficiency caused by 
mutation in the Bruton’s tyrosine kinase 
(Btk) gene. Mutation leads to reduced 
numbers (<2%) or total absence of B cells 
which results in low immunoglobulin levels. 
 
 Affected males are characterised by a 
high susceptibility to recurrent bacterial 
infection with onset in infancy or early 
childhood that persists for life. Treatment 
can prevent premature death. Thus the 
early detection and diagnosis of XLA is 
crucial.  
PREVALENCE:  XLA affects approximately 1 in 200 000 individuals. 
Aapproximately 90% of  XLA patients have mutation in their Btk gene, & this is seen as the most 
common type of Agammaglobulinemia. 
 
 Medical and public awareness of Primary Immunodeficiency is scarce and thus not many 
clinical diagnoses of this sort has been made (known). 
 
HOW CAN YOU HELP ?? 
We are currently in search of (male) patients presumed to have XLA. 
 
WHAT TO LOOK FOR / CHARACTERISTICS OF TYPICAL XLA : 
-  low to undetectable serum immunoglobulin levels 
-  low to no B cells (less than 2% of peripheral lymphocytes) 
-  increased predisposition to bacterial infection 
 
 Ethical clearance / permission was obtained for this investigation  
 A consent form will be sent to each participating individual 
PROJECT TITLE   
Real Time PCR as a diagnostic tool for 
detecting Btk mutations in 
Agammaglobulinaemia  
 
AIM  
The aim of this project is to determine the 
spectrum of Btk mutation and to develop a cost 
effective, reliable diagnostic Real Time PCR 
detection method for genetic abnormalities 
associated with the Bruton’s tyrosine kinase 
(Btk), primary humoral immunodeficiency.  
 
ENVISAGED OUTCOMES 
To determine the spectrum of Btk mutation in 
the SA population and to develop a Real Time 
PCR based diagnostic test for the most 
common Btk gene mutations. This will be useful 
for the early diagnosis of X-linked 
agammaglobulinemia. 
 
Appendix A
Contact: Melanie Leo  (MSc. Medical Microbiology Stellenbosch University) 
Email: 14393921@sun.ac.za
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BRUTON’S TYROSINE KINASE GENE 
Accession # U78027 (36721bp) 
Indicating introns,  exons in bold and primer pairs (forward in blue, and reverse in red). 
 
ORIGIN       
        1 CTCAGACTGT CCTTCCTCTC TGGACTGTAA GAATATGTCT CCAGGGCCAG TGTCTGCTGC 
  61 gatcgagtcc caccttccaa gtcctggcat ctcaatgcat ctgggaagct acctgcatta 
      121 AGTCAGGACT GAGgtgggtc tggggtatgg caggggctgg gcagcagcag caatgtacct 
      181 tgcttgggac ccctaaaaac cagagagaca gcatggctgg tgccatttat cagctagtgg 
      241 aggaggctga cggagggtgg gagtgtcatc agcacaaggc cctggcagtc ccttctggtg 
      
 
    10801 ctaggtagct aggctgaggg ggaaccaaga gggatgagga ttaatgtcct gggtcctcag 
    10861 gaactttcat tatcaacagC ACACAGGTGA ACTCCAGAAA GAAGAAGCTA TGGCCGCAGT 
    10921 GATTCTGGAG AGCATCTTTC TGAAGCGATC CCAACAGAAA AAGAAAACAT CACCTCTAAA 
    10981 CTTCAAGAAG CGCCTGTTTC TCTTGACCGT GCACAAACTC TCCTACTATG AGTATGACTT 
    11041 TGAACGTGGG gtaagtttct cgactatgaa aactgagttt caagatatca aggacttggc 
    11101 cttagatctt tcttggggaa gaggtaaatt ttcgttggta ggaggagggg agtagaatgg 
 
    11461 cacctcactt tgttgaatga ttagataaca aaatctaatc atctggttgc ttaatccctc 
    11521 ttaatctttc tccattttct tcctcattct acttctcagA GAAGAGGCAG TAAGAAGGGT 
    11581 TCAATAGATG TTGAGAAGAT CACTTGTGTT GAAACAGTGG TTCCTGAAAA AAATCCTCCT 
    11641 CCAGAAAGAC AGATTCCGgt aagaagagac caatgtctga gatggggaac agcagatttg 
    11701 aagaaatttg caacatttaa attctctgta aatagactgg tgatgctgtg caacgtggaa 
    11761 cacggtcaag tttcctttaa aaattcttca ctctaccata ttggttataa agaatcttag 
 
    14341 tccctattgg cctatagaaa gtaatcacta agaatcagcc ttgtctgtgc aggagaaact 
    14401 tctgaagcca cagcaaaagg cttctagtac ctaaggaaat tcagaaaaga gcaatgcatc 
    14461 aaccaataac cattttttct tatttcatta cagAGAAGAG GTGAAGAGTC CAGTGAAATG 
    14521 GAGCAAATTT CAATCATTGA AAGGTTCCCT TATCCCTTCC AGgtgagtta ttttctctca 
    14581 ccaaatctcg aaaggcccct gtaacacaat tagaaggggt ggtggggtgc agggcagagg 
    14641 gaaggctacg aggacccagt gaatagaagt tgaggtggac aaggatgctg aaccaagaaa 
 
    15961 ttcacataac ctgaacacca ttgctgactg aagattctgc ctttctttgt tttctacaat 
    16021 aaatatacaa attgtcccct aagattagta ctttcaaggt ctttctcctt ttttctgaat 
    16081 cctaactgct gaagtCTGTG TTTTCATCGA CCCAGGTTGT ATATGATGAA GGGCCTCTCT 
    16141 ACGTCTTCTC CCCAACTGAA GAACTAAGGA AGCGGTGGAT TCACCAGCTC AAAAACGgtg 
    16201 agaattattt ggaaaataaa tgtttccaaa gaaagaagga aaggaaggaa gaggagatag 
    16261 acgggaggaa aaggaaagaa ggaagagaga aacgagaaag aaagagaaag gagaaacgta 
 
    23341 gtcatgtgag ccaactggtc ctgtgatctg ctctccttca gggtggccaa ggagggggca 
    23401 gttgcttgaa gttcaccact aagctcaaag aggaaaacat gcaaatggtg gcttctcctc 
    23461 catgtcagat gtgatctctc tcttctttcc tgctacagTA ATCCGGTACA ACAGTGATCT 
    23521 GGTTCAGAAA TATCACCCTT GCTTCTGGAT CGATGGGCAG TATCTCTGCT GCTCTCAGAC 
    23581 AGCCAAAAAT GCTATGGGCT GCCAAATTTT GGAGAACAGG AATGGAAgta agcaatctga 
    23641 tcgatataat ttctttctcc tttgactgtt tccatcactc tcccaagggt ctgtcaagcc 
    23701 cagggtcata gcataaggtt gtacactttg ggtgctaaac aaagggtcct gggggaggga 
 
 
    23821 atgcctagct actttttcta acttgcctaa aggcactcaa tatggacggc aaagtccctg 
    23881 accaaacctg tccttggccc ctttcctaaa gtgcattcca tatcatcact ggcttcttgt 
    23941 tttgcagGCT TAAAACCTGG GAGTTCTCAC CGGAAGACAA AAAAGCCTCT TCCCCCAACG 
    24001 CCTGAGGAGG ACCAGgtata cagggaaact gggtgctgcc actgcttaaa tggaaactta 
    24061 tagtcaagcc ctaagaacac actagagtct tagaattacc ctgggacttg gcagtgttaa 
    24121 ttggtattct tgctaagatg ggggatttgt tcttctaatt aggatttcct cctcgatgga 
     
    
    25261 tgcaaggctg agaactcctg cactggtgct taaaaatggt tgttgaatga ctgctgagta 
    25321 atattttagt atgcctgatt tgggtgtctt gagtaagcca gagagttggg agagaagaga 
    25381 agagtgcttg gtatcttgac aaaccctcct accttttctc ctaactacat agATCTTGAA 
    25441 AAAGCCACTA CCGCCTGAGC CAGCAGCAGC ACCAGTCTCC ACAAGTGAGC TGAAAAAGGT 
    25501 TGTGGCCCTT TATGATTACA TGCCAATGAA TGCAAATGAT CTACAGCTGC GGAAGGGTGA 
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    25561 TGAATATTTT ATCTTGGAGG AAAGCAACTT ACCATGGTGG AGAGCACGAG ATAAAAATGG 
    25621 gtgagtccac accagccctt cctgagcctg gtgcctgccc actccctaca cgcaaaaagt 
     
 
 
    25681 gctgcggcat aattcccgtg atcagcatcc tcatcagaga ctgttcttcc cacaccagac 
    25861 cacctcactg gctcactgcc taaccatgca tcagagacat gattgtcttt gagggaggtg 
    25921 catgatacat atacctccat ttgagatttg ttctgagctc agggacgtgg gcatatgaat 
    25981 ctgtctcctg gaggctgggg aggtgctgga tgaactgcca cattgtttcc TTCACAGGCA 
    26041 GGAAGGCTAC ATTCCTAGTA ACTATGTCAC TGAAGCAGAA GACTCCATAG AAATGTATGA 
    26101 gtaagtatgt ttatgtcagt ccacaatctt ccaggaggaa ctctctctct ctatatatat 
    26161 atatatttat ttatttatat atattttata tatatttata tatatatata acacacacaa 
 
 
    26701 gctatgcaca tgacagatgc tcagtaaata gggtttgagt gagttgactg aatcactgac 
    26761 atggacaagc cctggagggt gctgtaacct ccaatctgct tatgaccagg agccactcaa 
    26821 gcagcactct cccttcacag GTGGTATTCC AAACACATGA CTCGGAGTCA GGCTGAGCAA 
    26881 CTGCTAAAGC AAGAGGTAAG TGTGGAACCA CTAGCACACA GCATTCTCCT TGCATAAGTG 
    26941 AGGATCTTGA ACTGAGGGCC TGTTCTGCCC CCTACCTTTG GGCAAGGCAG TGTCAaagct 
    27001 gccatcgtct gggatcccaa ttacaccatt ttttttgttt ttgtttttct gagacggact 
    27061 ctcggtctgt cacccaggct ggagtgcagt ggcgtgatct gggctcactg caacctccgc 
 
 
    27361 gctgtagctc aagcgtggaa cttggcagta aaatcagggg ttgttctatt ttctctctca 
    27421 agtttgggca ggtgggatgc aggtgtgagc accacttcct cctacagaca gCTTCTTTTT 
    27481 CGTTGTTTCA GGGGAAAGAA GGAGGTTTCA TTGTCAGAGA CTCCAGCAAA GCTGGCAAAT 
    27541 ATACAGTGTC TGTGTTTGCT AAATCCACAG Ggtgagtgct actattccaa ggccctgagg 
    27601 acaaagaaca ggggtaccct cctaatagct ccttgatgct gtgcccgtcc cacttcctct 
 
 
    27661 gtctctgaaa ctcaaaactc atctcacttc acttcctggg ttctgttgac ctttgtgccc 
    27721 aagttactga ctaagcatcc acttcttcag ggacccTCAA GGGGTGATAC GTCATTATGT 
    27781 TGTGTGTTCC ACACCTCAGA GCCAGTATTA CCTGGCTGAG AAGCACCTTT TCAGCACCAT 
    27841 CCCTGAGCTC ATTAACTACC ATCAGCACAA CTCTGCAGgt gagtaccagg ggcaactgag 
    27901 aagggagtta cagacaccag gataagcaat gcaggacaag gtgataagag gaagaatctg 
    27961 cctcacagga cagtgtgaat tcactgtgaa aggaaatccc tgtgatactg ggtagaagct 
    
   
    28501 tactagaaag atacacaccg gaagtgtgag gctttaagtg aggatgtgtg aggcatccca 
    28561 cctcctacac cacaccaaca gcatgacctc tctctctgtt tcagGACTCA TATCCAGGCT 
    28621 CAAATATCCA GTGTCTCAAC AAAACAAGAA TGCACCTTCC ACTGCAGGCC TGGGATACGG 
    28681 TAACTCCTTA TTTCTCTGGG GTAGGGTGGA CTGGCCAGTT GCAAAAACTA CCTTTGCTGg 
    28741 ccttgcctta gggagtgtcc ttgaggtaca ctgttctgca gcagctgcct caaggacgct 
    28801 caagacagat ccaagcaaaa gttattcact gattttcttc ctctagtggc tacgactggg 
    28861 actgcaaaaa catagattca taaagggctt tgtcgttgtc ttgggtcttt ttgtctttta 
 
 
    29101 aaagacagat tagtacttct aaaaatttcc cttttactag ttttcctatt tctaccccag 
    29161 tagggatttt tgtctattgt aagaattata cattcatgac cccaaagaat cacaccaaga 
    29221 ctttattgtt aggatcatgg gaAATTGATC CAAAGGACCT GACCTTCTTG AAGGAGCTGG 
    29281 GGACTGGACA ATTTGGGGTA GTGAAGTATG GGAAATGGAG AGGCCAGTAC GACGTGGCCA 
    29341 TCAAGATGAT CAAAGAAGGC TCCATGTCTG AAGATGAATT CATTGAAGAA GCCAAAGTCA 
    29401 TGATgtgagt tatagcccaa actcaactct caatctattt gctggagtct aggaattcac 
    29461 acaacaaccc actgaggctt aaagatgact tacagtaaga gaggtttggg acgagggact 
 
   
 
    29761 agcacttttg agatttaggg tgggaaagag gaaaataaac ttgctggtgt gaccccttat 
    29821 ctgatgctct actcctaggt cagccccttc ctccccagcc cctttattgc tattatgcag 
    29881 agccaaaagg agaagactag ttccttgcct ttcctgtagG AATCTTTCCC ATGAGAAGCT 
    29941 GGTGCAGTTG TATGGCGTCT GCACCAAGCA GCGCCCCATC TTCATCATCA CTGAGTACAT 
    30001 GGCCAATGGC TGCCTCCTGA ACTACCTGAG GGAGATGCGC CACCGCTTCC AGACTCAGCA 
    30061 GCTGCTAGAG ATGTGCAAGG ATGTCTGTGA AGCCATGGAA TACCTGGAGT CAAAGCAGTT 
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    30121 CCTTCACCGA GACCTGgtgg gaccttagaa ggattggcct aggacaaagg gctgatgggg 
    30181 tggaagtagc agtggaagat atatcataca tggttgaggg gggctgctgg tgccatcatt 
    30241 tcaattttat ctagaaagta ctataagtta ggcgtgcctc tgccccagtg ctgagcccat 
 
  
    31381 gtagtcgaag gagatgaagc ttccctggct tcattctact ggtcagcaga agctttgtgc 
    31441 ctttaacctc tgtgctgggg acggagtctc actggtctct gtttgcacta CAGGCAGCTC 
    31501 GAAACTGTTT GGTAAACGAT CAAGGAGTTG TTAAAGTATC TGATTTCGGC CTGTCCAGgt 
    31561 gagtgtggct ttttcatctt tccctccaga agtaaaaata gcacagtatg aaacatgggt 
    31621 aggtgttaca gttttaatcc tctccttttc ttttttttct cattctagcg ttttctgccg 
 
    32041 attcgttaaa agtaacgttt gtagaagata ctagttgagg aggagagact tttgagaaag 
    32101 cctgtgtgtg tttgtgacac tcttgtgacc gtgccaagaa aacgtaagca aatatcaagc 
    32161 ctccaaatcc taatgcaaca agtcctgaat cccttgcagG TATGTCCTGG ATGATGAATA 
    32221 CACAAGCTCA GTAGGCTCCA AATTTCCAGT CCGGTGGTCC CCACCGGAAG TCCTGATGTA 
    32281 TAGCAAGTTC AGCAGCAAAT CTGACATTTG GGCTTTTGgt aagtggataa gattacacag 
    32341 attatacagc tcaaaggata agaaatgcaa tggggaaaat tcacactttg caacctccac 
    32401 agagatattg ttcttgcttt cattcttcca atccttgggg agtgcttact gtgtgtcagc 
 
 
 
    32701 agaaatttgg gcaaaatata aaaagcacag agcggggaac caactgattc taatctttga 
    32761 ggttgatcta ggaagactag gacccctgct atccaaaaag actgcaaacc aatttaataa 
    32821 tttttttcac cttctagGGG TTTTGATGTG GGAAATTTAC TCCCTGGGGA AGATGCCATA 
    32881 TGAGAGATTT ACTAACAGTG AGACTGCTGA ACACATTGCC CAAGGCCTAC GTCTCTACAG 
    32941 GCCTCATCTG GCTTCAGAGA AGGTATATAC CATCATGTAC AGTTGCTGGC ATGAGgtaag 
    33001 tgctttatta ggatctctta aattatttcc ttgaatctac ttgcccattt agctggccat 
    33061 tcagccacca aagactgata gctgcacaca ttcttttttt tccttttttt ttttttttaa 
 
 
    36121 atgctactgg gcatagagca tatatttaat aaacatttgc tgcttactca ttgcatttcc 
    36181 cttgaattct ggattctagc cactctaaca ctttactttt tctttggttt tagaaagCAG 
    36241 ATGAGCGTCC CACTTTCAAA ATTCTTCTGA GCAATATTCT AGATGTCATG GATGAAGAAT 
    36301 CCTGAGCTCG CCAATAAGCT TCTTGGTTCT ACTTCTCTTC TCCACAAGCC CCAATTTCAC 
    36361 TTTCTCAGAG GAAATCCCAA GCTTAGGAGC CCTGGAGCCT TTGTGCTCCC ACTCAATACA 
    36421 AAAAGGCCCC TCTCTACATC TGGGAATGCA CCTCTTCTTT GATTCCCTGG GATAGTGGCT 
    36481 TCTGAGCAAA GGCCAAGAAA TTATTGTGCC TGAAATTTCC CGAGAGAATT AAGACAGACT 
    36541 GAATTTGCGA TGAAAATATT TTTTAGGAGG GAGGATGTAA ATAGCCGCAC AAAGGGGTCC 
    36601 AACAGCTCTT TGAGTAGGCA TTTGGTAGAG CTTGGGGGTG TGTGTGTGGG GGTGGACCGA 
    36661 ATTTGGCAAG AATGAAATGG TGTCATAAAG ATGGGAGGGG AGGGTGTTTT GATAAAATAA 
    36721 A // 
 
 
 
 
 
 
 
 
 
 
 
Exon16
Exon17
Exon18
Exon19
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Appendix C 
Primer Sequences     
Primer Pairs from Conley et al. (1994) 
 
Primer Pair 5' Primer 3' Primer Exon Domain Size (bp) Annealing Temp (°C) 
1 TCAGACTGTCCTTCCTCT AGGTACACATTGCTGCTGCT 1 5' Untranslated 160 55 
2 TGGGTCCTCAGGAACTTTC CAAGAGAAACAGGCGCTT 2 5' Unique 155 58 
3 CTGGAGAGCATCTTTTCTG GATCTAAGGCCAAGTCCT 2 5' Unique 186 53 
4 CCATTTTCTTCCTCATTC GTTCCCCATCTCAGACAT 3 5' Unique 160 56 
5 GGCTTCTAGTACCTAAGG CCTTTCGAGATTTGGTGA 4 5' Unique 176 56 
6 CCTAACTGCTGAAGTCTG TCCAAATAATTCTCACCG 5 5' Unique 160 53 
7 CCTCCATGTCAGATGTGA TGGAAACAGTCAAAGGAG 6 5' Unique 220 56 
8 TCCATATCACTGGCT GTGTTCTTAGGGCTTGAC 7 5' Unique 164 56 
9 CCCTCCTACCTTTTCTCC TTCCGCAGCTGTAGATCA 8 5' Unique/ SH3 148 50 
10 AGGTTGTGGCCCTTTATG AAGGGCTGGTGTGGACTC 8 SH3 142 50 
11 CTGGATGAACTGCCACAT AGAGAGAGTTCCTCCTGG 9 SH3 140 55 
12 TCTGCTTATGACCAGGAG CCTCACTTATGCAAGGAG 10 SH2 150 56 
13 ACTTCCTCCTACAGACAG CAAGGAGCTATTAGGAGG 11 SH2 180 56 
14 TCCTGGGTTCTGTTGACC GTAATACTGGCTCTGAGG 12 SH2 118 53 
15 GACCCTCAAGGGGTGATA AACTCCCTTCTCAGTTGC 12 SH2 155 58 
16 CCAACAGCATGACCTCTC GGCAAGGCCAGCAAAGGT 13 SH2/ SH1 170 60 
17 GACCCCAAAGAATCACAC GAGAGTTGAGTTTGGGCT 14 SH1 230 60 
18 GGACAATTTGGGGTAGTG GAGAGTTGAGTTTGGGCT 14 SH1 155 58 
19 CTAGTTCCTTGCCTTTCC TAGCAGCTGAGTCTG 15 SH1 170 51 
20 AACTACCTGAGGGAGATG ACTGCCTACTTCCACCCA 15 SH1 180 58 
21 TCACTGGTCTCTGTTTGC CTGTAACACCTACCCATG 16 SH1 160 58 
22 GCAACAAGTCCTGAATCC TGGAGGTTGCAAAGTGTG 17 SH1 175 56 
23 TCTAGGAAGACTAGGACC TTGGGCAATGTGTTCAGC 18 SH1 155 53 
24 AGGTGAGACTGCTGAACAC CTATCAGTCTTTGGTGGC 18 SH1 186 53 
25 CTGGATTCTAGCCACTCT AGAAGCTTATTGGCGAGC 19 SH1/ 3' Untranslated 130 56 
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Appendix D 
 
Identification of the Novel Mutation and the effects thereof.  
 
Figure 1.  Nucleotide Sequence of the genomic DNA of the Normal exon (PubMed MIM300300) 
Mutated nucleotide is indicated in bold print and the the variant sequence found in Patients 003 
and 004 
 
 
 
Figure 2. An amino acid and nucleotide representation of a section of normal exon 16 and 17 of 
the Btk gene. 
Area of interest in Red 
NORMAL SEQ ... TTC GGC CTG TCC AGG TAT GTC CTG GAT GAT GAA TAC ACA AGC TCA GTA GGC ... 
MUTATED SEQ ... TTC GGC CTG TCA GGT ATG TCC TGG ATG ATG AAT ACA CAA GCT CAG TAG 
 
Figure 3. Nucleotide sequence of a section of normal Btk gene and the truncated Btk gene produced due to 
the mutation found in Patient 004. 
Affected amino acid in red 
Stop Codon in brown 
 (…)  indicate that only part of the sequence is represented. 
540   543  545     550     555  
F G L S R Y V L D D E Y T S S V G 
TTC GGC CTG TCC AGG TAT GTC CTG GAT GAT GAA TAC ACA AGC TCA GTA GGC 
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Appendix E 
 
Abbreviations 
 
Primary Immunodeficiency disorder       PID 
X-linked Agammaglobulinaemia                                                   XLA    
Bruton’s tyrosine kinase                                                              Btk 
Intravenous gammaglobulin replacement therapy                       IVIg 
National Research Foundation      NRF 
National Health Laboratory Services      NHLS 
B cell receptors            BCR  
T cell receptors                    TCR 
T Helper cells          TH 
Cytotoxic T cells                     Tc 
          AIDS 
B cell linker protein         BLNK 
Immunoglobulins                                                                          Ig 
Alpha             α  
Beta              ß  
Mu                         μ  
Lambda             λ 
Subcutaneous treatment                                                                  SCIg 
Cytoplasmic protein-tyrosine kinases       PTKs 
Bone Marrow kinase gene on the X chromosome     Bmx 
IL2-inducible T cell kinases                                Itk 
Tec protein tyrosine kinase                                                                              Tec 
Progenitor B cells          Pro-B cells 
Precursor B cells         Pre-B cells 
Phospholipase C 2          PLC-  2 
Nuclear factor kappa-light-chain-enhancer of activated B cells       NF-κB  
Pleckstrin homology  domain                                                                            PH 
Tec homology domain           TH 
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Src homology 3 domain                                 SH3 
Src homology 2 domain                     SH2 
Catalytic kinase domain        SH1/ Kinase 
Common Variable Immunodeficiency disorder                   CVID  
Primary Immunodeficiency South Africa Registry                    PISA 
Polymerase Chain Reaction             PCR 
Immunodeficiency mutation database        IDbase 
Not determine             N.D 
Ethylenediaminetetraacetic acid         EDTA 
Normal                         N 
Deletion                           Del 
Arginine              R 
Histidine              H 
Tryptophan              W 
